Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -56.36% is 50% below its 2-year average of -37.45%, near the low end of its 2-year range (-56.36%–-25.73%).
As of the fiscal period ended Tuesday, June 30, 2026. 44.44% below its 12-month average of -39.02%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -56.36%.
RETURN ON EQUITY (ROE)
-56.36%
RETURN ON EQUITY (ROE) AVG TTM
-39.02%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-44.44%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.76%
median of 687 covered companies
CURRENT VS SECTOR MEDIAN
-38.28%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$283.87M
Return on Equity (ROE)
-56.36%
TTM Avg
-39.02%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.92M
Return on Equity (ROE)
-27.36%
TTM Avg
-12.73%
3Y Avg
-30.52%
5Y Avg
-39.12%
Market Cap
$285.83M
Return on Equity (ROE)
-49.11%
TTM Avg
-50.02%
3Y Avg
-153.47%
5Y Avg
-149.41%
Market Cap
$285.37M
Return on Equity (ROE)
-135.62%
TTM Avg
-521.17%
3Y Avg
-307.05%
5Y Avg
43.03%
Market Cap
$287.53M
Return on Equity (ROE)
-18.38%
TTM Avg
-37.53%
3Y Avg
-22.34%
5Y Avg
-10.93%
Market Cap
$288.35M
Return on Equity (ROE)
-16.18%
TTM Avg
-23.55%
3Y Avg
59.17%
5Y Avg
22.66%
Market Cap
$280.29M
Return on Equity (ROE)
-21.41%
TTM Avg
-11.72%
3Y Avg
-50.56%
5Y Avg
-98.46%
Market Cap
$272.50M
Return on Equity (ROE)
-5.95%
TTM Avg
-61.29%
3Y Avg
-64.14%
5Y Avg
-41.58%
Market Cap
$293.47M
Return on Equity (ROE)
-135.50%
TTM Avg
-129.54%
3Y Avg
-84.04%
5Y Avg
-77.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $283.87M | -56.36% | -39.02% | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | -27.36% | -12.73% | -30.52% | -39.12% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.83M | -49.11% | -50.02% | -153.47% | -149.41% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | -135.62% | -521.17% | -307.05% | 43.03% |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.53M | -18.38% | -37.53% | -22.34% | -10.93% |
| Standard BioTools Inc. (LAB)vs › | $288.35M | -16.18% | -23.55% | 59.17% | 22.66% |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | -21.41% | -11.72% | -50.56% | -98.46% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $272.50M | -5.95% | -61.29% | -64.14% | -41.58% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.47M | -135.50% | -129.54% | -84.04% | -77.00% |
| Fate Therapeutics, Inc. (FATE)vs › | $274.50M | -82.12% | -62.12% | -56.53% | -50.41% |
ROE
-56.4%
ROA
-48.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -56.36% |
| 2026-03-31 | -41.39% |
| 2025-12-31 | -32.61% |
| 2025-09-30 | -25.73% |
| 2024-12-31 | -39.36% |
| 2024-09-30 | -29.26% |
